Skip to main content

Table 2 Eligibility for Short Course Regimen by Clinical Criteria and DST Performed. a. Participants with MDR-TB Eligible for Short Course Treatment, by DST Performed

From: Few eligible for the newly recommended short course MDR-TB regimen at a large Mumbai private clinic

Resistance Status

Xpert Only, N = 559

2nd-Line LPA Only,a N = 466

Testing R, FQ, INJ, Z, and E, N = 432b

Testing R, FQ, INJ, Z, E, Eto, and Cfz, N = 407b

 

# Eligible or Resistant / # Tested (%)c

# Eligible or Resistant / # Tested (%)c

# Eligible or Resistant / # Tested (%)c

# Eligible or Resistant / # Tested (%)c

Eligible for Short Course

559 / 559 (100)

118 / 466 (25.3)

16 / 432 (3.7)

14 / 407 (3.4)

Resistant to FQ or INJ

N/A

348 / 466 (74.7)

320 / 432 (74.1)

304 / 407 (74.7)

Resistant to Z or E

N/A

N/A

408 / 432 (94.4)

386 / 407 (94.8)

Resistant to FQ, INJ, Z, or E

N/A

N/A

416 / 432 (96.3)

391 / 407 (96.1)

Resistant to FQ, INJ, Z, E, Eto, or Cfz

N/A

N/A

N/A

393 / 407 (96.6)

  1. a2nd-line LPA tests for susceptibility to isoniazid, rifampin, fluoroquinolones, and 2nd-line injectables (amikacin, capreomycin, or kanamycin)
  2. bR rifampin, FQ fluoroquinolone, INJ 2nd-line injectable, Z pyrazinamide, E ethambutol, Eto ethionamide, Cfz clofazimine
  3. cPercentages reported reflect number of participants with resistance or susceptibility divided by number of participants who completed susceptibility testing for each drug. As a result, the number of participants in the denominator is not the same in all rows